Lead Product(s): Budesonide
Therapeutic Area: Nephrology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Calliditas does not anticipate a significant impact of the Covid-19 pandemic on the ongoing clinical activities related to NefIgArd, the company's pivotal Phase 3 IgA nephropathy trial.